Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • FAQ
  • Accessibility Statement

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Checkpoint Therapeutics Reports Full-Year 2020 Financial Results and Recent Corporate Highlights

Mar 09, 2021

Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences

Mar 04, 2021

Mustang Bio to Participate in Three March 2021 Virtual Investor Conferences

Mar 04, 2021

Checkpoint Therapeutics to Participate in H.C. Wainwright Global Life Sciences Virtual Conference

Mar 04, 2021

Checkpoint Therapeutics Announces Formation of Scientific Advisory Board

Mar 01, 2021

Caelum Biosciences Announces Collaborations with the Amyloidosis Advocacy Community and Support of Amyloidosis Awareness Month

Mar 01, 2021

Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®

Feb 26, 2021

Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®

Feb 26, 2021

Cyprium Therapeutics, a Fortress Biotech Partner Company, and Sentynl Therapeutics, a Wholly-owned Subsidiary of the Zydus Group, Sign Development and Asset Purchase Agreement for Cyprium Therapeutics’ Copper Histidinate Product Candidate for Treatment of Menkes Disease

Feb 24, 2021

Aevitas Therapeutics Appoints Markus Peters, Ph.D., M.Sc., as Chief Executive Officer

Feb 22, 2021
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2025 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap